| Literature DB >> 27270288 |
Meritxell García-Quintanilla1, José M Caro-Vega1, Marina R Pulido1, Patricia Moreno-Martínez1, Jerónimo Pachón1, Michael J McConnell2.
Abstract
LpxC inhibitors have generally shown poor in vitro activity against Acinetobacter baumannii We show that the LpxC inhibitor PF-5081090 inhibits lipid A biosynthesis, as determined by silver staining and measurements of endotoxin levels, and significantly increases cell permeability. The presence of PF-5081090 at 32 mg/liter increased susceptibility to rifampin, vancomycin, azithromycin, imipenem, and amikacin but had no effect on susceptibility to ciprofloxacin and tigecycline. Potentiating existing antibiotics with LpxC inhibitors may represent an alternative treatment strategy for multidrug-resistant A. baumannii.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27270288 PMCID: PMC4958213 DOI: 10.1128/AAC.00407-16
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191